Septal Thickness and Alcohol Septal Ablation (2) Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, (3) Copenhagen University Hospital, Gentofte Hospital, Hellerup, Denmark, (4) Oslo University Hospital, Rikshospitalet, Oslo, Norway, and (5) Karolinska University Hospital, Stockholm, Sweden. All centers are tertiary referral centers for ASA. All patients treated with echocardiography-guided first-time ASA were included in the study. HCM was diagnosed in accordance with guidelines. 15, 16 Data on 652 patients (age: 57±14 years) were included. Survival status was obtained from national registries 7.1±4.2 years after ASA.
For technical reasons, measurement of interventricular septum dimension 17 (IVSd) could only be analyzed in 531 patients (age: 56±14 years; follow-up: 7.9±4.0 years). Excluded patients are described in the Table I in the Data Supplement. ASA was performed after careful consideration of different treatment options and after informed consent was obtained. 12 The study was in agreement with local ethics regulations.
Alcohol Septal Ablation
ASA was performed according to a previously reported protocol. 18 In brief, a septal perforating artery supplying the obstructing part of the septum was identified on the coronary angiogram and chosen as target vessel. After occlusion of the septal target branch by a percutaneous coronary intervention balloon, the area of perfusion was visualized by echocardiography after injection of 1 to 2 mL of echocardiography contrast medium. 19 The risk of backflow into the left anterior descending artery was tested for by injection of radiographic contrast into the target vessel during fluoroscopy. Under analgesic medication, a volume of ≈0.1 mL 96% alcohol per mm septum was slowly injected into the target vessel through the balloon catheter. The alcohol volume was adjusted in each case based on anatomy and septal thickness according to previous reports. 12, [20] [21] [22] The balloon was deflated and removed after 10 minutes. The occlusion of the target vessel was verified angiographically at the end of the procedure.
ASA Indication and Study Outcomes
The indication for ASA was: (1) presence of severe drug refractory symptoms (New York Heart Association [NYHA] class 3-4 symptoms, in combination with (2) LVOT gradients ≥50 mm Hg at rest or ≥100 mm Hg during provocation by a Valsalva maneuver, or, alternatively, by dynamic exercise testing. Canadian Cardiology Society (CCS) class 3 to 4 angina or repeated syncope was considered alternative symptomatic indications.
The effect of ASA on these parameters has previously been reported. 11, 12, 14 In this study, we analyzed the influence of baseline septal hypertrophy on ASA efficacy in terms of clinical end points and longterm survival after ASA.
Statistics
Baseline data, follow-up data, and survival status were analyzed using SAS statistical software package version 9.3. Data are presented as mean±SD when normally distributed or median (quartiles) when non-normally distributed. Proportions are presented as percentages (%). A paired Student t test was used for paired comparisons of continuous variables. Unpaired Student t test was used for comparison of continuous variables between 2 groups and ANOVA was used for testing of continuous variables between multiple groups. Proportions were compared with χ 2 test or Fishers exact test. All comparisons of categorical outcomes were unpaired. For presentation of data, patients were stratified into mild (IVSd <20 mm), moderate (IVSd 20-24 mm), and severe (IVSd ≥25 mm) hypertrophy. The term massive hypertrophy was used for IVSd ≥30 mm. 9 Summary data are presented according to this stratification. Regression analysis of continuous variables was performed by linear regression with IVSd treated as a continuous variable. Regression analyses of categorical variables were performed by logistic regression with IVSd treated as a continuous variable. The effect of IVSd, as continuous variable, on survival was analyzed in: (1) a univariate Cox regression model and (2) a Cox proportional hazards model adjusted for the possible effects of predefined confounders (age, sex, body mass index [BMI], and ASA-performing center). Other baseline and procedural variables were tested in a stepwise forward regression analysis and kept in the model if significance (P<0.05) was reached. No postprocedural variables were allowed in the model. The model was controlled for interactions between variables. Hazard ratios (HRs) were calculated for each of the moderate and severe hypertrophy group versus the mild hypertrophy group. HRs were also calculated treating IVSd as continuous variable and represent the HR for 1 mm increment of IVSd. Results are presented as HR with 95% confidence intervals (CI). Time-to-event curves were compared with the Log-rank test. A 2-sided P<0.05 was considered significant.
Results

Baseline Characteristics
Data on 531 patients (age: 56±14 years; males 55%; follow-up: 7.9±4.0 years) was analyzed. Forty-eight patients died during 4189 patient-years (mortality rate: 1.1% per year). Cardiovascular death was confirmed in 18 patients (38%), and 16 of these deaths were categorized as sudden cardiac death. Ten patients (21%) died of cancer diseases and 5 (10%) from neurological diseases. The remaining 6 patients died of other noncardiovascular diseases. The cause of death remained uncertain in 9 patients. An implantable cardioverter defibrillator was implanted in 11 patients (3 for secondary prevention) before and in 34 patients (7 for secondary prevention) after ASA. Baseline characteristics stratified by intervals of IVSd are shown in Table 1 . IVSd was correlated with left ventricular posterior wall dimension (β=0.58; P<0.001; r 2 =0.15), increased left atrial diameter (LAd) (β=0.13; P<0.001; r 2 =0.05) and LVOT gradients at rest (β=0.01; P=0.030; r 2 =0.009). There were no correlations between symptoms and LVOT gradient during Valsalva maneuver (Table 1) .
Cardiac Remodeling After ASA
Left atrial dimension decreased from 48±7 to 46±7 mm (P<0.001) with no association between baseline IVSd and the reduction of left atrial dimension (P=0.934). Left ventricular end-diastolic dimension increased from 45±6 mm to 46±6 mm (P=0.003), and baseline IVSd was correlated with
WHAT IS KNOWN
• Severe hypertrophy is associated with reduced survival and sudden cardiac death in patients with HCM.
• ASA is a safe and effective treatment of LVOT obstruction in patients with hypertrophic obstructive cardiomyopathy.
• Survival after ASA is comparable to survival in the background population.
WHAT THE STUDY ADDS
• ASA is an effective treatment of LVOT obstruction and associated symptoms in patients with severe septal hypertrophy.
• Severe septal hypertrophy is associated with reduced survival also after ASA.
the increase in left ventricular end-diastolic dimension (0.2 mm left ventricular end-diastolic dimension increase per mm IVSd; P=0.007; r 2 =0.018). Left ventricular posterior wall dimension was reduced from 13±3 to 12±2 mm (P<0.001) with a weak association between left ventricular posterior wall dimension reduction and baseline IVSd (P=0.063). Left ventricular ejection fraction was reduced from 67±12% to 66±11% (P=0.010), and the reduction was not associated with baseline IVSd.
Effect of IVSd on Clinical Outcome After ASA
The symptomatic and echocardiographic effects of ASA were assessed 0.6±0.6 years after the ASA. The LVOT gradient was reduced from 60 (35-80) to 7 (1-20) mm Hg (P<0.001) at rest and from 110 (90-140) to 30 (1-60) mm Hg (P<0.001) during Valsalva maneuver. There was no correlation between baseline IVSd and the absolute reduction in LVOT gradient at rest (P=0.883) or during Valsalva maneuver (P=0.885) ( Figure 1 ). The proportion of patients in NYHA class 3 to 4 was reduced from 86% to 10% with no association between baseline IVSd and NYHA class before (P=0.603) or after (P=0.067) ASA ( Figure 2 ). The proportion of patients in CCS class 3 to 4 was reduced from 26% to 2%, and there was no association between baseline IVSd and CCS class before (P=0.199) and after (P=0.106) ASA. ASA reduced the CCS class in all groups, however, 3% of patients (7/227) with baseline IVSd <20 mm had remaining CCS class 3 to 4 angina after ASA ( Table 2 ). The proportion of patients with syncope decreased from 25% to 2% after ASA with no association between baseline IVSd and the proportion of patients with syncope before (P=0.820) or after (P=0.426) ASA. Results are presented as mean±SD, median (quartiles), or as percentage. AF indicates atrial fibrillation; BMI, body mass index; CCS, Canadian Cardiology Society; EF, ejection fraction; IVSd, interventricular septum dimension; LAd, left atrial diameter; LVEDd, left ventricle end-diastolic dimension; LVOT, left ventricle outflow tract; LVPWd, left ventricular posterior wall dimension; and NYHA, New York Heart Association.
Figure 1.
Reduction of the left ventricular outflow tract (LVOT) gradients at rest and during Valsalva maneuver after alcohol septal ablation (ASA) stratified according to baseline interventricular septum dimension (IVSd). There were no significant differences between the responses to ASA in different IVSd categories.
The 10-year survival after ASA was 83%. IVSd, handled as a continuous variable, was not significantly associated with survival in a unadjusted univariate regression analysis (P=0.051).
In a multivariable proportional hazard model adjusted for the possible confounding effects of age (P<0.001), sex (P=0.220), BMI (P=0.020), and ASA-performing center (P=0.039), there was an inverse association between baseline IVSd and survival (HR for 1 mm increment, 1.13; CI, 1.05-1.21; P<0.001). The multivariate model satisfied the proportional hazards assumption for IVSd as a continuous variable. There were no interactions between IVSd and age (P=0.480), BMI (P=0.337), sex (P=0.116), or ASA-performing center (P=0.086), respectively ( Table II in the Data Supplement) .
Other possible predictors of all-cause mortality were tested in a stepwise forward regression analysis without reaching significance (Table 3 ). When analyzing IVSd as a categorical variable in a multivariate model that satisfy the proportional hazards assumption, the IVSd ≥25 mm was associated with a 5-fold risk of all-cause mortality (HR, 5.0; CI, 2.1-12; P<0.001), and IVSd 20 to 24 mm was not associated with reduced all-cause mortality (P=0.323) compared with patients with IVSd <20 mm ( Table 2 ). Baseline IVSd was inversely correlated with age (β=−0.03; P<0.001; r 2 =0.03). There was no association between IVSd and BMI (P=0.851). IVSd in males was 20.1±3.9 mm and 19.5±4.1 mm in females (P=0.134). Mean IVSd ranges from 17.1±4.1 to 20.3±3.8 mm 
Discussion
The major novel findings in this study of outcomes after ASA were that the success rate of ASA was independent of septal thickness and that survival after ASA was inversely related to septal thickness. Compared with patients with mild hypertrophy, we found a 5-fold risk of all-cause mortality in patients with IVSd≥25 mm (63/531 patients) after adjustments for confounding effects of age, sex, BMI, and ASA-treating center. The degree of hypertrophy has been shown to correlate with the severity of diastolic dysfunction and intramyocardial fibrosis, confirming that IVSd is a readily available important structural marker of prognosis and disease severity in patients with HCM with or without ASA. The degree of hypertrophy in patients with HCM has previously been negatively associated with survival in studies by Spirito et al 2 (n=480) and Elliott et al 7 (n=630), whereas a smaller study by Olivotto et al 23 (n=237) failed to confirm this relationship. Likewise, Desai et al. 6 failed to confirm the association using univariate analysis in a large myectomy cohort (n=699).
In this study, we demonstrated that the univariate analysis of the association between IVSd and survival did not reach significance. Importantly, we adjusted the model with predefined possible confounders and found that age was negatively correlated with IVSd. Thus, the expected relatively good survival in the youngest patients may be counterbalanced by reduced survival in cases with more pronounced hypertrophy. It is not surprising that this relationship is missed in a univariate analysis. By adjusting for confounders, we demonstrated a clinically important 5-fold risk of death in subjects with IVSd≥25 mm compared with patients with IVSd<20 mm. In this manner, we confirmed the inverse relationship between hypertrophy and survival in our ASAtreated HCM cohort, but in absence of procedure-related association with survival, our findings support the long-term safety of the ASA procedure. These results and the reduced survival compared with the background population reported Gray: IVSd<20 mm (age: 58±13 years); black: IVSd 20 to 24 mm (age: 56±15 years); dashed: IVSd≥25 mm (age: 49±15 years). Log-rank test P=0.03. Septal Thickness and Alcohol Septal Ablation by Sorajja et al 9 in a general HCM cohort with massive hypertrophy (≥30 mm) illustrate that although HCM is a benign condition in the majority of patients, small subsets of patients are at increased risk, and patients with pronounced hypertrophy represent such a subset.
In this multicenter approach, we accumulated a ASAtreated HCM cohort sufficiently large to separately analyze clinical outcomes of ASA in the subgroup of patients with severe hypertrophy (IVSd≥25 mm). We found a homogenous effect of ASA on LVOT gradients and symptoms in patients with all degrees of hypertrophy. The LVOT gradients at rest and during Valsalva maneuver were higher in patients with more pronounced hypertrophy at baseline, and this relation was preserved after ASA, leaving mostly insignificant residual gradients in patients with the highest IVSd at baseline. In potential agreement with our findings, Sorajja et al 13 (n=177) found that residual LVOT gradients after ASA were associated with reduced survival, but effects of baseline hypertrophy on survival was not assessed in that study. In this study, we analyzed the clinical outcome 0.6±0.6 years after ASA. A previous study from the Scandinavian HOCM (hypertrophic obstructive cardiomyopathy) database have shown that most reinterventions (myectomy or re-ASA) were performed between 12 and 24 month after the first ASA procedure, and LVOT gradients after 24 months were stable with low reinterventions rates. 14 Thus, the final long-term residual LVOT gradients in this cohort may be lower than that reported in this study.
Limitations
In this multicenter cohort, the number of procedure-related data are limited, and the number of treated septal branches is not available. It is important to notice that this cohort represents a cohort of patients with HCM selected for suitability of performing ASA. Hemodynamic and anatomic features have been thoroughly evaluated, comorbidities have been assessed, and treatment options have been discussed in each case before deciding on treatment strategy. In this process, many patients have been selected for other treatment options such as medical or surgical therapy and implantable cardioverter defibrillator implantation for primary sudden cardiac death prevention. Such patient selection represents an inherent limitation to studies of this kind. Thus, this cohort has been subject to profound selection, and similar results can only be expected in patients selected likewise.
Conclusions
ASA had equal effects on LVOT gradients and symptoms regardless of the degree of septal hypertrophy. Severe septal hypertrophy before ASA remained a marker of reduced survival after ASA with a 5-fold increased risk of all-cause mortality in patients with IVSd >25 mm compared with patients with IVSd <20 mm.
ASA can be successfully used in treatment of LVOT obstruction caused by any degree of septal hypertrophy in patients with HCM. The excess mortality in patients with severe septal hypertrophy before ASA illuminates an unresolved issue in treatment of HCM patients in general and patients treated with ASA in particular. Severe hypertrophy is considered to be a risk factor for sudden cardiac death, and much effort has been invested in analyzing the risk of sudden cardiac death in HCM. With contemporary HCM treatment, the risk of sudden cardiac death is probably <1% per year, which implies certain limitation to the effort of developing improved risk stratification algorithms. This study returns the attention to reduction of all-cause mortality as the most important clinical goal and end point in future studies. The survival rates in contemporary HCM cohorts have been reported to be close to those of the background population, but these data may conceal poor outcomes of patients with severe hypertrophy. Attention should be raised on the subgroup of patients with severe hypertrophy (≥25 mm) that in this study exhibited a 5-fold increased risk of death compared with other patients with HCM treated with ASA.
